In D2 & D4, one study was classified as igh
References Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al
"Karpa gives entrepreneurs, clinics, wellness brands, and creators the most complete white-label telehealth platform to quickly launch GLP-1, peptide therapy, hormone replacement therapy, and other cash-pay programs nationwide without building the technology or clinical operations from scratch." The timing reflects clear market momentum
Gastrointestinal side effects are most common during dose escalation and may improve with slower titration or temporary interruption of treatment
"Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus"